6.44 USD
▲+0.09+1.42%
盘后 6.32 -1.86%
2026-11-19
市值
$697.57M
市盈率
—
EPS
-1.72
股息率
—
52 周区间
4.40 – 11.45
成交量
1.74M
Beta
2.63
目标价
18.71
52W 低 4.4052W 高 11.45
价格走势
公司简介
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treat...